舒尼替尼治疗转移性非透明细胞肾癌的疗效观察  

Efficacy of Sunitinib in treating metastatic non-clear cell renal cell carcinoma

作　　者：施国海[1] 姚旭东[1] 张世林[1] 戴波[1] 张海梁[1] 沈益君[1] 朱耀[1] 朱一平[1] 马春光[1] 肖文军[1] 秦晓健[1] 林国文[1] 杨立峰[1] 叶定伟[1] 

机构地区：[1]上海复旦大学附属肿瘤医院泌尿外科,200032

出　　处：《中华泌尿外科杂志》2011年第10期711-713,共3页Chinese Journal of Urology

摘　　要：目的初步探讨舒尼替尼治疗转移性非透明细胞。肾癌的疗效。方法非透明细胞肾癌22例。男14例，女8例。年龄29～76岁，中位年龄46岁。根治性肾切除术后出现转移14例，初诊时诊断为肾癌伴转移行减瘤性肾切除术8例。病理证实乳头状癌12例，嫌色细胞癌1例，集合管癌3例，未分类癌6例。转移部位包括肺、淋巴结、肾上腺，骨和肝脏。舒尼替尼50／13g／d，口服，每天1次，治疗4周休息2周。治疗时间4．5—24．0个月，中位时间11个月。随访4．5～25．0个月，中位时间14个月。结果22例疾病控制率为73％（16／22）。部分缓解4例（18％），其中乳头状癌3例，嫌色细胞癌1例，转移灶位于肺或肺加腹膜后淋巴结，或腹膜后淋巴结。疾病稳定〉3个月12例（55％），用药3个疗程内疾病进展6例（27％）。结论舒尼替尼治疗转移性。肾乳头状癌、嫌色细胞癌、集合管癌、未分类癌有效，对淋巴结转移及肺转移者的疗效相对较好。Objective To investigate the efficacy of Sunitinib in treating metastatic non-clear cell renal cell carcinoma （RCC）. Methods Twenty-two metastatic non-clear cell subtype renal cell carcinoma patients with a median age of 46 years （29 -76 years） were treated with Sunitinib. Fourteen cases were found have metastasis post radical nephrectomy, and the remaining eight cases with metastasis received cy- toreductive surgery. Pathological diagnosis showed 12 papillary RCCs, one chromophobe RCC, three collecting duct RCCs, and six unclassified RCCs. The metastatic lesions were located in the lung, lymph nodes, adrenal gland, bone, liver, and thyroid gland. The patients were given the treatment of sunitinib 50 mg qd four weeks on and two weeks off. The median time of treatment was 11 months （4.5 - 24 months）. Results The objective control rate was 73%. Three papillary RCC and one chromophobe RCC reached partial remission （PR） and 12 cases maintained stable disease （SD） for more than 12 weeks. And the remaining six cases progressed （PD）. Conclusions Sunitinib has definitive efficacy in metastatic papillary RCC, chromophobe RCC, collecting duct RCC and unclassified RCC. Metastatic lesions in lungs and lymph nodes might be more sensitive to Sunitinib.

关 键 词：肾肿瘤 癌 肿瘤转移 舒尼替尼 

分 类 号：R737.11[医药卫生—肿瘤]